Zymeworks Stock Quote ZYME - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

8.26

Bid

7.66

Ask

8.34

Volume

561,745

7.97 Day's Range 8.30

6.015 52 Week Range 13.14

Market Cap

453.754M

Previous Close

8.11

Open

8.12

Last Trade

8.29

Last Trade Time

Financial Volume

$ 4,588,501

VWAP

8.1683

Average Volume (3m)

588,727

Shares Outstanding

70,568,222

Dividend Yield

PE Ratio

-3.82

Earnings Per Share (EPS)

-1.68

Revenue

76.3M

Net Profit

-118.67M

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.zymeworks.com

Headquarters

North Vancouver, British Columbia, Can

Founded

1970

Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was $8.11. Over the last year, Zymeworks shares have traded in a share price range of $ 6.015 to $ 13.14.

Zymeworks currently has 70,568,222 shares outstanding. The market capitalization of Zymeworks is $453.75 million. Zymeworks has a price to earnings ratio (PE ratio) of -3.82.

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form RW - Registration Withdrawal Request

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation...

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.39	-4.50867052023	8.65	8.98	7.97	734786	8.55966312	CS
4	-2.21	-21.1079274117	10.47	10.56	7.97	601544	9.04514468	CS
12	-2.68	-24.4972577697	10.94	13.14	7.97	588727	10.55851889	CS
26	1.26	18	7	13.14	6.5124	524488	9.98510917	CS
52	-0.86	-9.4298245614	9.12	13.14	6.015	516592	8.94438632	CS
156	1.88	29.4670846395	6.38	13.14	6.015	621209	8.77584107	CS
260	1.88	29.4670846395	6.38	13.14	6.015	621209	8.77584107	CS

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M

Symbol

Price

Vol.